CA2286451A1 — Hormone-sensitive lipase mediated male infertility
Assigned to Canadian Gene Cure Foundation · Expires 2001-04-14 · 25y expired
What this patent protects
In various aspects, the invention provides pharmacologic and genomic methods of inhibiting fertility in a male animal, such as human male contraception, involving the manipulation of the activity of hormone-sensitive lipase, including inhibiting the activity of a hormone-sensitiv…
USPTO Abstract
In various aspects, the invention provides pharmacologic and genomic methods of inhibiting fertility in a male animal, such as human male contraception, involving the manipulation of the activity of hormone-sensitive lipase, including inhibiting the activity of a hormone-sensitive lipase in the animal. In another aspect, the invention discloses the use of hormone-sensitive lipase as a target in screening assays that may be used to identify compounds that modulate male fertility. In another aspect, the present invention identifies a condition of male infertility caused by hormone-sensitive lipase deficiency.
Drugs covered by this patent
- Copiktra (DUVELISIB) · Secura
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.